Evaluation of the Role of Tramadol 50mg as an Analgesic During Outpatient Hysteroscopy

Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT02068209
Collaborator
(none)
140
1
2
10
14

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the role of Tramadol 50mg in reducing pain during outpatient hysteroscopy.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This study is a prospective double blinded randomised controlled trial. 140 women will be recruited from the office hysteroscopy clinic in Cairo university hospitals.

All patients attending the outpatient hysteroscopy clinic will be invited to participate in the study. The invitation will include a clear full explanation of the study and patients will provide written consents. Only patients consenting to participate will be included in the trial.

Tramadol and placebo will be enclosed in sealed envelopes which will be numbered using a computer generated random table. Neither the patient nor the physician will be aware of the drug used. Patients will be categorized into 2 groups: Group I who will receive Tramadol 50mg (Tramadol, October Pharma, Giza, Egypt) 1 hour before the procedure, group II who will received a placebo acting as the control group.

Full history will be taken followed by general and local examination. The procedure will be done in the lithotomy position. Hysteroscopy will be done using a 5mm outer diameter continuous flow hysteroscope with a French working channel and a 30 degrees direction of view provided by Techno GmbH and CO. The hysteroscope will be introduced using the vaginoscopy technique, in which no speculum will be used. The cervix will be detected and the external os will be identified using the hysteroscope. The hysteroscope will be introduced in the uterine cavity. Saline will be used as the distension medium and the pressure will be set at 100mm Hg. The anterior wall, posterior wall and tubal ostea will be visualized, any polyps, adhesions septa, congenital malformations or submucous fibroids will be noted.

Base line characteristics will be compared and the main outcome measure will be patients' pain perception during the procedure and 30 minutes later, this will be determined using a visual analogue scale.

Study Design

Study Type:
Interventional
Actual Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Role of Tramadol 50mg in Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo Controlled Trial.
Study Start Date :
May 1, 2014
Actual Primary Completion Date :
Mar 1, 2015
Actual Study Completion Date :
Mar 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Tramadol

Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy

Drug: Tramadol
patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
Other Names:
  • Tramadol 50mg
  • Placebo Comparator: Placebo

    Patients will receive a placebo 1 hour before the procedure.

    Drug: Placebo
    patients will receive a placebo 1 hour before outpatient hysteroscopy

    Outcome Measures

    Primary Outcome Measures

    1. Pain perceived by the patient during the procedure [10 minutes after starting the procedure.]

      Pain will be assessed by a visual analogue scale 10 minutes after starting the procedure.

    Secondary Outcome Measures

    1. Pain perceived by the patient 30 minutes after the procedure. [30 minutes after the procedure.]

      The level of pain will be assessed 30 minutes after the procedure by a visual analogue scale.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients referred for outpatient hysteroscopy

    • Consent to the procedure

    Exclusion Criteria:
    • Premenstrual patients

    • Known cardiac disease

    • Known allergy to Tramadol

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cairo University Hospitals Cairo Egypt

    Sponsors and Collaborators

    • Cairo University

    Investigators

    • Principal Investigator: AbdelGany MA Hassan, MRCOG, MD, Cairo University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    AbdelGany Hassan, Dr Hassan, Cairo University
    ClinicalTrials.gov Identifier:
    NCT02068209
    Other Study ID Numbers:
    • Gany-123
    First Posted:
    Feb 21, 2014
    Last Update Posted:
    Apr 6, 2015
    Last Verified:
    Apr 1, 2015
    Keywords provided by AbdelGany Hassan, Dr Hassan, Cairo University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2015